Neurizon Therapeutics Limited (ASX:NUZ) has applied to ASX for quotation of 61,764,704 ordinary fully paid shares with an issue date of 9 November 2026, priced at AUD $0.068 per security as part of a placement previously announced to the market on 2 November 2026.

Key Points

  • 61,764,704 ordinary fully paid shares applied for quotation at an issue price of AUD $0.068 each
  • Securities issued for cash consideration in Australian dollars, with an issue date of 9 November 2026
  • Following quotation, total quoted ordinary fully paid shares on issue will be 853,417,069
  • A further 1,470,588 placement shares to directors remain subject to shareholder approval at a general meeting expected in December 2026
  • A Share Purchase Plan also remains to be completed as part of the broader transaction

Placement Details and Issue Terms

The 61,764,704 ordinary fully paid shares were issued at AUD $0.068 per security for cash consideration in Australian dollars. The filing states the securities form part of a transaction previously notified to ASX via an Appendix 3B lodged on 2 November 2026, titled "New - Proposed issue of securities - NUZ." The quotation application was submitted on 6 November 2026, with the securities carrying an issue date of 9 November 2026. Further details of the transaction were directed to Neurizon's company disclosure dated 2 November 2026.

Further Securities Yet to Be Issued

According to the filing, the transaction has not been fully completed. A further 1,470,588 placement shares are to be issued to directors of Neurizon and/or their respective nominees, subject to shareholder approval at a general meeting expected to be held in December 2026. Additionally, the filing discloses that shares under a Share Purchase Plan are yet to be issued as part of the same transaction. These two components remain outstanding at the time of the quotation application.

Issued Capital Following Quotation

Following the quotation of the 61,764,704 shares, Neurizon's total quoted ordinary fully paid shares on issue will stand at 853,417,069. The company also has a range of unquoted securities on issue, including options expiring 5 February 2028 exercisable at $0.26 (384,000), options expiring 30 June 2032 exercisable at $0.20 (9,539,210), options expiring 31 August 2033 exercisable at $0.16 (2,044,025), options expiring 31 August 2034 exercisable at $0.0594 (5,947,668), and 16,245,860 performance rights, according to the filing.